Trial reportSchizophrenia bulletin2013
Clonidine normalizes sensorimotor gating deficits in patients with schizophrenia on stable medication.
Trial report in Schizophrenia bulletin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Clonidine normalizes levels of P50 gating in patients with schizophrenia on stable medication.Schizophrenia bulletin · 2014Trial
- Abnormal cortical topographic patterns associated with auditory verbal hallucination in first-episode schizophrenia.Translational psychiatry · 2025Article
- Reliability and state-dependency of EEG connectivity, complexity and network characteristics.Scientific reports · 2025Article
- The Effect of Exogenous Ketones on Signs and Symptoms of Schizophrenia Spectrum and Bipolar Disorders: Study Protocol for a Triple-Blind, Randomized, Controlled Crossover Pilot Study.Current developments in nutrition · 2025Article
- Evaluating the association between steroid hormones and filtering of sensory information in healthy women.Neuroscience applied · 2024Article
- Identification of a psychiatric risk gene NISCH at 3p21.1 GWAS locus mediating dendritic spine morphogenesis and cognitive function.BMC medicine · 2023Article
- Early Schizophrenia and Bipolar Disorder Patients Display Reduced Neural Prepulse Inhibition.Brain sciences · 2022Article
- Characterizing Creative Thinking and Creative Achievements in Relation to Symptoms of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder.Frontiers in psychiatry · 2022Article
- Distribution of the Noradrenaline Innervation and Adrenoceptors in the Macaque Monkey Thalamus.Cerebral cortex (New York, N.Y. : 1991) · 2021Article
- Review
- Sensory filtering disruption caused by poly I:C - Timing of exposure and other experimental considerations.Brain, behavior, & immunity - health · 2020Article
- Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension.Schizophrenia research · 2018Article
- The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review.Frontiers in psychiatry · 2017Review
- Comparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Article
- Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.The international journal of neuropsychopharmacology · 2015Article
- Could vagus nerve stimulation target hippocampal hyperactivity to improve cognition in schizophrenia?Frontiers in psychiatry · 2015Review
- Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- α2-Adrenoceptors are targets for antipsychotic drugs.Psychopharmacology · 2014Review
- Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS.Schizophrenia research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive deficits form core features in schizophrenia. Several studies have shown improvements in prefrontal cognitive function by α 2 -agonists in schizophrenia. In the present study, it was investigated whether clonidine (an α 2 -adrenoceptor agonist) could normalize sensorimotor gating deficits in schizophrenia.
methodsIn a double blind, placebo controlled, randomized, yet balanced, cross-over experiment, 20 male schizophrenia patients on stable medication were assessed in an auditory prepulse inhibition (PPI), sensitization, and habituation of the startle reflex paradigm on 5 occasions: once after oral administration of placebo and after a single dose of 25, 50, 75, and 150 µg of clonidine. Their results were compared with 20 age- and gender-matched healthy volunteers, who received no treatment.
resultsIn the placebo treatment, patients showed deficient PPI and sensitization, yet normal habituation compared with the controls. Except the highest dose, all dosages of clonidine significantly increased percentage PPI in the patients compared with placebo, to such levels that it no longer differed significantly from the healthy controls. However, none of the dosages increased sensitization or influenced habituation.
conclusionsThis is the first study to show that even a single low dose of clonidine added to the medical treatment of patients with schizophrenia who are clinically stable on their antipsychotic medication not only significantly ameliorates their PPI deficits, but also normalizes them. The results have a potentially high clinical relevance for the medical treatment of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.